AFFILIATIONS
1 Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
2 Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
3 Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
4 Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
5 Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
6 Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
7 Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
8 Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
9 Shanghai YaKe Biotechnology Ltd, Shanghai, China
10 Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
11 Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
ABSTRACT
Background Standard immunochemotherapy yields suboptimal outcomes in patients with newly diagnosed high-risk large B-cell lymphoma (LBCL). The ZUMA-12 trial demonstrated the feasibility of CD19 chimeric antigen receptor (CAR) T-cell therapy as a first-line treatment, yet more data are needed to support its broader application in this setting. Furthermore, how to design better integrated strategies to further enhance the efficacy and safety of frontline CAR T-cell therapy remains an open question.
Methods In this single-center phase II trial, we enrolled patients with newly diagnosed high-risk LBCL. Patients received two cycles of rituximab, lenalidomide, and Zanubrutinib (ZR2), followed by CD19 CAR T-cell infusion. The primary endpoint was complete response (CR) rate after CAR T-cell therapy.
Results A total of 43 patients were enrolled (median age, 69 years; 44% ≥70). After ZR2 debulking, the overall response rate was 92.9%, with a CR rate of 33.3%. Among the 40 patients who received CAR T-cell therapy, the primary endpoint was met, with a CR rate of 97.5% (95% CI: 86.8%-99.9%). At a median follow-up of 25.6 months, estimated 2-year progression-free survival and overall survival were 84% and 97.6%, respectively. Cytokine release syndrome occurred in 25% of patients (grade 3 in 2.5%); no neurotoxicity or treatment-related deaths occurred.
Conclusions In this phase II trial, ZR2 debulking followed by sequential CD19 CAR T-cell therapy resulted in a high CR rate, durable responses, and a favorable safety profile in patients with newly diagnosed high-risk LBCL. Larger randomized trials are warranted. (ClinicalTrials.gov number, NCT04661020.)
DISCLOSURES
Mingming Zhang, PhD: No relevant conflicts of interest to declare.